External broker reports(aggregated public sources), CCZ Statton Equities

CCZ Statton Equities

External broker reports(aggregated public sources)

CCZ is a leading Australian stockbroking firm providing stockbroking and wealth generation services to private clients and institutional investors. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<div>
<ul>
<li>The clinical trials backlog is now $110.5m (+26% pcp), driven by another strong quarter of clinical trial sales of $17.9m (-56% pcp).</li>
<li>The backlog from clinical trials has underpinned Q1'FY23 group revenue of $8.9m (-27% pcp).</li>
<li>The clinical trial segment contributed $7.8m of revenue (-30% pcp), and the healthcare segment remained flat with $1.1m. Delays in revenue are not of concern.</li>
</ul>
</div>
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.



The clinical trials backlog is now $110.5m (+26% pcp), driven by another strong quarter of clinical trial sales of $17.9m (-56% pcp).
The backlog from clinical trials has underpinned Q1'FY23 group revenue of $8.9m (-27% pcp).
The clinical trial segment contributed $7.8m of revenue (-30% pcp), and the healthcare segment remained flat with $1.1m. Delays in revenue are not of concern.


Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Cogstate - Backlog Builds for Alzheimer's Trials, but Revenue Delayed

<ul><li>Eisai Co.,Ltd has announced its Lecanemab confirmatory phase 3 study meeting its primary and secondary endpoints.</li><li>The drug reduced clinical cognitive decline by 27% compared to a placebo in a study involving 1,795 participants with early Alzheimer's disease.</li><li>Eisai will continue to seek drug approval for Lecanemab in the US, Japan and Europe.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Eisai Co.,Ltd has announced its Lecanemab confirmatory phase 3 study meeting its primary and secondary endpoints.The drug reduced clinical cognitive decline by 27% compared to a placebo in a study involving 1,795 participants with early Alzheimer's disease.Eisai will continue to seek drug approval for Lecanemab in the US, Japan and Europe.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Cogstate - Lecanemab Strikes 'home Run' for Alzheimer's Drug Development

<ul><li>Largely pre-announced, CGS recorded a FY22 group revenue of $45.0m, up +38% pcp, with the clinical trial segment attributing $40.3m, up +41% pcp.</li><li>Total backlog revenue at $139.1m, up +37% pcp, with a record $82.5m new contracts signed in the year.</li><li>CGS's market share of Alzheimer's disease clinical trials increased to 17% with 16 trials (13% with 12 trials in Dec-21).</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Largely pre-announced, CGS recorded a FY22 group revenue of $45.0m, up +38% pcp, with the clinical trial segment attributing $40.3m, up +41% pcp.Total backlog revenue at $139.1m, up +37% pcp, with a record $82.5m new contracts signed in the year.CGS's market share of Alzheimer's disease clinical trials increased to 17% with 16 trials (13% with 12 trials in Dec-21).Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Cogstate - Phase 3 Readouts Underpin the Next Phase of Accelerated Growth

Australia

CogState Limited manufactures and distributes diagnostic and therapeutic products associated with neurological disorders and the measurement of cognitive functions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00